Clinical study
Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia
| Status | Not yet recruiting |
|---|---|
| Type | Trial |
| Countries | Location not listed |
| Conditions studied | VAP - Ventilator Associated Pneumonia |
| Study years | 2025 (estimated)–2028 (estimated) |
| Entry review | 2026-10-03 |
Participation
Check the study record or contact the study team for current recruitment and eligibility.
Study eligibility
Inclusion Criteria: 1. Diagnosed with ventilator-associated pneumonia (VAP); 2. Identified infection with MDR Klebsiella pneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa via MROSE evaluation and antimicrobial susceptibility testing (AST) from this or other tertiary hospitals; 3. Aged 18 to 85 years; 4. Written informed consent obtained from the patient or legal guardian. Exclusion Criteria: 1. Pregnant or breastfeeding women; 2. FiO₂ ≥ 70% or PEEP ≥ 15 cmH₂O; 3. Hemodynamic instability (vasopressor dose increased by ≥30% in the last 6 hours or norepinephrine \> 0.5 μg/kg/min); 4. Known allergy to phage components.
Study description
The purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial infections.
Study registrations
| ClinicalTrials.gov | NCT07202234 |
|---|
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Study ID | nct07202234 |
|---|